News

Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting at our Alnwick facility.

A £6 million project expands Quotient Sciences' Alnwick, UK into a state-of-the-art drug substance manufacturing facility that can deliver integrated support for customers from candidate selection through to early clinical development and beyond.

Richard Castledine talks to Pharmaceutical Technology about moving off the critical path and streamlining strategies for drug substance synthesis and manufacturing

Paul Quigley, Principal Research Fellow, Drug Substance at Quotient Sciences, discusses the acceleration of development timelines between drug substance and drug product with Pharmaceutical Technology.

Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over the next three years.